In GLP-1R and GCGR, ECL1 forms a short -helix structure adjacent to the extracellular tips of TM2 in GLP-1R and TM3 in GCGR (Fig
GLP-1 drugs which include semaglutide, the drug in Novo Nordisks Ozempic and Wegovy, and tirzepatide, the drug in Lillys Mounjaro and Zepbound have soared in popularity in recent years
Acute cholecystitis: Hospital admission for IV fluids, analgesia, antibiotics (typically piperacillin-tazobactam or a cephalosporin plus metronidazole per local antibiogram), and urgent surgery consultation
Easy-to-mix powdered format, ideal for on-the-go use
Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury
A 2023 review in the Journal of Clinical Endocrinology & Metabolism highlighted that GLP-1s can delay gastric emptying significantly, especially at higher doses or early in treatment.44 Another study found that just over 5% of patients experience gastroparesis and it was more likely when using liraglutide or dulaglutide when compared with semaglutide.45 A 2024 cross-sectional analysis in Pharmaceuticals examined the GI side effects of semaglutide, dulaglutide, liraglutide, and exenatide in over 10,000 adults with T2DM or obesity from the National Institutes of Health All of Us cohort.45 They found that abdominal pain was the most frequently reported GI issue (57.6%), followed by constipation, diarrhea, nausea/vomiting, GI bleeding, gastroparesis, and pancreatitis
